CoChat

Importance of Drug Pharmacokinetics at the Site of Action

Open access
Rizk, ML, Zou, L, Savic, RM, Dooley, KE · 2017 · Clinical and Translational Science
Cited by 131

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Pharmacological activity depends on adequate drug levels at the effect site, but access to these sites for pharmacokinetic sampling is often limited. Thus, we often rely on plasma concentrations as surrogates in efforts to understand exposure–response relationships. Recent advances in analytical and quantitative methodologies allow for more robust and often noninvasive assessments of drug pharmacokinetics at the site of action. This review highlights the advances made in estimating drug exposures in several compartments of interest. Due to difficulty in accessing relevant tissues or biological fluids to measure drug levels, plasma drug concentrations are often collected with the hope that they will correlate with or be informative about exposures in compartments of interest, which is often found to be the case. Even between structurally similar compounds, however, penetration into these matrices may vary widely, and so exclusive use of plasma exposure in pharmacokinetic–pharmacodynamic (PK/PD) models may lead to suboptimal assessment of exposure–response relationships and inaccurate dose selection in certain circumstances. Differences in penetration between even structurally similar compounds into a given site may be due to a host of factors ranging from permeability to local metabolism to physicochemical properties to the role of drug transporters in efflux or uptake. Novel experimental and quantitative methods have been developed to assess drug levels at the site of action across therapies and disease areas. For central nervous system (CNS) diseases, the measurement of drug levels in the cerebrospinal fluid (CSF) using lumbar puncture and even directly in the brain using imaging or microdialysis has provided insight into drug penetration across the blood–brain barrier and helped characterize the compartmental pharmacology of such drugs. In oncology, linking information about drug penetration into solid tumors with radiologic outcomes provides a greater understanding of relevant exposure–response relationships. For HIV, characterization of drug distribution into the genital tract and the colorectum, sites of potential HIV exposure, has informed the development of preexposure prophylaxis. For antibacterials, lung penetration studies using microdialysis or invasive bronchiolar lavage have been instrumental in projecting drugs and doses with sufficient local exposure to be efficacious against the bacterial pathogens that cause pneumonia, while the assessment of PK in urine provides insight into the likelihood of successful treatment of urinary tract infections. As analytical and quantitative techniques have continued to evolve to allow for the assessment of drug levels at these various sites of action, so has our knowledge regarding the role of drug-metabolizing enzymes and transporters in the uptake and efflux of drugs in relevant compartments.1, 2 Our ability to assess the role a transporter may play in the distribution and elimination of a given drug has expanded with the development of increasingly complex in vitro systems and growing knowledge about how to translate such in vitro results to clinical impact. Together with quantitative approaches such as physiology-based pharmacokinetic (PBPK) modeling, we now have the tools at our disposal to predict drug disposition and how factors such as patient demographics, pharmacogenomics, or coadministration with other drugs affect it. There is a wealth of knowledge regarding the development and application of PBPK models that has been well described previously,3-5 both for small molecules and monoclonal antibodies.6, 7 With sufficient information about drug levels at the site of action, advances in population PK modeling can allow for the effect site to be treated as a separate compartment, thus bridging effect site PK to plasma PK. Once mathematical linkages between effect site and plasma PK are established, inferences about effect site PK can be made in subsequent experiments in which only plasma PK is collected, especially in cases where site-of-disease PK measurement is invasive or inconvenient. However, one must be careful to consider situations where nonlinearities may limit the ability to extrapolate plasma PK to tissue levels under different scenarios. Such limitations may arise due to saturation of drug transport pathways, nonlinear or concentration-dependent protein binding that differentially impacts fluids and tissues, or similarly nonlinear or concentration-dependent drug clearance. Additionally, often information regarding effect site PK is gathered in situations where limited sampling takes place. The dynamic changes in drug level in the plasma and effect site are often not synchronous, and thus sampling limitations may lead to an inadequate understanding of the relationship between plasma and effect site drug levels. Additionally, systems-level models such as quantitative systems pharmacology (QSP) and physiology-based pharmacodynamic (PBPD) model

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cts.12448

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 131

Metadata

Authors
Rizk, M., Zou, L., Savic, R., & Dooley, K.
Venue
Clinical and Translational Science
Publisher
Wiley
Published
2017-02-03
Volume
10
Issue
3
Pages
133-142
ISSN
  • 1752-8054 (ISSN-L)
  • 1752-8062
OpenAlex
W2583770167
Cited by
131
References
12
FWCI
11.53
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.